Huanfeng Yang

Huanfeng Yang is a biotech founder and CEO who has led Oricell Therapeutics (原启生物) since its inception. She serves as chairwoman and chief executive of the Shanghai-based cell therapy company, which focuses on solid tumor CAR-T therapies . Under her leadership, Oricell has advanced multiple programs through clinical trials, including its lead asset Ori-C101, which entered Phase II confirmatory trials as of mid-2026 . The company raised a $110 million pre-IPO round co-led by Qiming Venture Partners in April 2026 , adding to a $70 million Series C first tranche closed in January of that year . Yang holds a PhD and has represented Oricell at major scientific conferences, with her team's CAR-T clinical data earning three ASCO oral report selections through 2026 .